People wondering about timing flexibility with GLP-1 approaches can find relevant guidance in our article on taking GLP-1 a day early
GLP-1 Receptor Agonist Market Growth Drivers: Rising global metabolic disease burden and expanding GLP-1 clinical indications driving extraordinary pharmaceutical market growth The GLP-1 receptor agonist market's 17.61% CAGR reflects forces that are building in magnitude rather than plateauing
Participant characteristics Across all trials, participants mean HbA 1c at baseline was 66.47 mmol/mol (8.2%), mean body weight was 91.5 kg and mean age was 58 years (Table 1)
Current oncology reports , 13 , 71-76
Diabetes is a well-known risk factor for dementia, in part because high blood sugar levels can damage blood vessels throughout the body, including in the brain
Large cardiovascular outcome trials, including LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide), have provided valuable insights into lipid changes
